News

Article

Sponsored Content

Ethical, Biosafety, and Scientific Review Considerations in Hematology and Oncology Clinical Trials

Author(s):

WCG Clinical

The current oncology and hematology drug development pipeline features a wide array of large molecule therapeutics. As a result, clinical trial protocols have grown more complex, requiring sponsors, CROs, and research sites to tackle a variety of challenges that were less common with older, more traditional therapies.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!
Related Content
Site Logo
August 4th 2025

Leveraging remote-based regional hubs in FSP partnerships

PPD™ FSP solutions
Site Logo
August 4th 2025

Establishing a Bespoke Outsourcing Arrangement with Hybrid FSP/FSO Partnerships

PPD™ FSP solutions
Site Logo
August 4th 2025

2025 FSP Trends Report

PPD™ FSP solutions
Site Logo
August 4th 2025

Focus on biotech: Harnessing FSP engagements to deliver on-time, on-budget

PPD™ FSP solutions
Site Logo
August 4th 2025

FSP Outsourcing in Clinical Research: Trends and Opportunities

PPD
When drug developers choose the right outsourcing strategies in clinical research, they can gain significant benefits in terms of quality, efficiency, and operational success. In its third annual Functional Service Provider (FSP) Trends Report, Thermo Fisher Scientific’s clinical research business—PPD—gathered insights from 150 global biotech and pharma leaders to determine how FSP models help sponsors address common industry obstacles.
Site Logo
August 4th 2025

Unlock Commercial Growth through Data-Driven Patient and HCP Insights

Inovalon
Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
© 2025 MJH Life Sciences

All rights reserved.